Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2016 | Editorial

Ocriplasmin — variable efficacy?

Authors: David H. W. Steel, David Wong

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2016

Excerpt

For most vitreoretinal specialists, the adoption of ocriplasmin (OCP) into their practice remains controversial. This might be due to the varying experience, positive and negative, of individual practitioners. In this issue, in a meta-analysis of over 800 patients from 18 series, Chatziralli et al. showed that the rate of release of vitreomacular adhesion (VMA) was 46 % but with a very wide range (from 0 to 71 %) and wide standard deviation (21 %) between series [1]. If you are one of the surgeons getting a success rate of closer to 70 %, you might be enthusiastic; alternatively, surgeons getting nearer 0 % are likely to give up using OCP. There needs to be some explanation for this wide variation. …

Chatziralli I, Theodossiadis G, Xanthopoulou P, Miligkos M, Sivaprasad S, Theodossiadis P (2016) Ocriplasmin use for vitreomacular traction and macular hole: a meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Graefes Arch Clin Exp Ophthalmol [Epub ahead of print]

Stalmans P, Benz MS, Gandorfer A, MIVI-TRUST Study Group et al (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615CrossRefPubMed

Haller JA, Stalmans P, Benz MS, MIVI-TRUST Study Group et al (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122CrossRefPubMed

Elbendary AM, Elwan MM, Azzam HA, Eldeeb DR (2011) Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction. Curr Eye Res 36:534–539CrossRefPubMed

Costa Ede P, Rodrigues EB, Farah ME, Sebag J, Meyer CH (2011) Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy. Curr Pharm Biotechnol 12:410–422CrossRefPubMed

de Smet MD, Jonckx B, Vanhove M et al (2012) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213CrossRefPubMed

http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106290.htm. Accessed 19 May 2016

Steel DH, Parkes C, Papastavrou VT et al (2016) Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography. Eye (Lond) 30:740–745CrossRef

Title: Ocriplasmin — variable efficacy?
Authors: David H. W. Steel
David Wong
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3404-0

At a glance: The STEP trials

Springer Medicine

Ocriplasmin — variable efficacy?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2016

Re: “Incidence of post-cataract endophthalmitis with intracameral cefuroxime” letter to the editor

Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height

Intravitreal aflibercept for myopic choroidal neovascularization

Re: Cho et al. “Long-term visual outcome and prognostic factors of intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation”

Pupillary responses driven by ipRGCs and classical photoreceptors are impaired in glaucoma

Orbital Surgery (Esaso Course Series) Editors: R. Medel, L. M. Vásquez, F. Bandello, B. Corcóstegui (2014) ISBN: 978-3318026054 Publisher: Karger